Alixarx LLC Agrees To Pay $2.75M To Resolve Allegations

AlixaRx LLC agrees to pay $2.75 million to resolve allegations that it improperly dispensed controlled substances at long-term care facilities

ATLANTA (STL.News) AlixaRx, LLC, a national provider of pharmacy services to long-term care facilities, has agreed to pay the United States $2.75 million to resolve allegations that it violated federal law by, among other things, allowing opioids and other controlled substances to be dispensed without valid prescriptions between January 1, 2014 and December 13, 2017.

“The requirements of the Controlled Substances Act exist to ensure that dangerous drugs are not abused or diverted outside the DEA’s closed system of distribution,” said Acting U.S. Attorney Kurt R. Erskine. “As this settlement makes clear, these requirements are not optional, and our office will vigorously pursue claims against registrants that place their own bottom line over the safety of our citizens.”

“AlixaRx, LLC spun a web of deception when it engaged in unlawful dispensing practices by abusing the emergency prescription provisions of the Controlled Substance Act,” said the Special Agent in Charge of the DEA Atlanta Field Division Robert J. Murphy. “Such behavior allows for substances to be diverted and sold on the black market with no true measure of accountability. 

This News Alixarx LLC Agrees To Pay $2.75M To Resolve Allegations appeared first on STL.News.